---
schema_version: "secwatch.filing_event.v1"
accession: "0000927653-24-000121"
form_type: "8-K"
ticker: "MCK"
cik: "0000927653"
company_name: "MCKESSON CORP"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T05:02:46.660729+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# McKesson Q2 FY2025 revenue $93.7B (+21%), adj. EPS $7.07 (+13%), raises FY25 adj. EPS guidance

## Summary
- Revenue $93.7B, +21% YoY; GAAP diluted EPS $1.87 (down 62% vs $4.92); adjusted EPS $7.07 (+13%).
- Raises FY2025 adjusted EPS guidance to $32.40-$33.00 from $31.75-$32.55, implying 18-20% growth.
- Announced agreement to acquire controlling interest in Florida Cancer Specialists & Research Institute's Core Ventures.
- Announced agreement to sell Canada-based Rexall and Well.ca retail businesses.

## SEC filing metadata
- accession: 0000927653-24-000121
- form_type: 8-K
- ticker: MCK
- cik: 0000927653
- company_name: MCKESSON CORP
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/927653/000092765324000121/0000927653-24-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/927653/000092765324000121/mck-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000927653-24-000121
- JSON: https://secwatch.observer/filing/0000927653-24-000121.json
- Plain text: https://secwatch.observer/filing/0000927653-24-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.